Seminars in Radiation Oncology
Volume 17, Issue 1 , Pages 22-28 , January 2007

Definitive Chemoradiation in the Management of Locally Advanced Esophageal Cancer

  • Mohan Suntharalingam, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mohan Suntharalingam, MD, Department of Radiation Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, 22 South Greene Street, Gudelsky Building, Baltimore, MD 21201.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Earlam R, Cunha-Melo JR. Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg. 1980;67:457–461
  3. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67:381–390
  4. Harrison LE. Is esophageal cancer a surgical disease?. J Surg Oncol. 2000;75:227–231
  5. Purdy JA. The development of intensity modulated radiation oncology. In:  Sternick E editors. The Theory and Practice of Intensity Modulated Radiation Therapy. Madison, WI: Advanced Medical Publishing; 1997;p. 1–15
  6. Coia L, Engstrom P, Paul A. Long-term results of infusional 5-FU mitomycin-C and radiation as primary management of esophageal cancer. Int J Radiat Oncol Biol Phys. 1991;20:29–36
  7. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. [see comments] N Engl J Med. 1992;326:1593–1598
  8. al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. [published erratum appears in J Clin Oncol 15:866, 1997] J Clin Oncol. 1997;15:277–284
  9. Cooper JS, Guo MD, Herskovic A, et al. Radiation Therapy Oncology Group Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281:1623–1627
  10. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–1174
  11. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. [see comments] [published erratum appears in N Engl J Med 341:384, 1999] N Engl J Med. 1996;335:462–467
  12. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–313
  13. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–167
  14. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979–1984
  15. Bendenne L, Bouche O, Michel P, et al. Randomized phase III trial in locally advanced esophageal cancer: Radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol. 2002;21:422
  16. Bedenne L. Chemoradiation: an alternative to surgery for the curative treatment esophageal cancer?. Gastroenterol Clin Biol. 2005;29:551–556
  17. Bonnetain F, Bouche O, Michel P, et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): Chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol. 2006;17:827–834
  18. Stahl M, Wilke H, Stuschke M, et al. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol. 2005;131:67–72
  19. Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–183
  20. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900–908
  21. Brenner B, Ilson DH, Minsky BD. Treatment of localized esophageal cancer. Semin Oncol. 2004;31:554–565
  22. Minsky BD, Neuberg D, Kelsen DP, et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1999;43:517–523
  23. Moiseyenko VM, Ajani JA, Tjulandin SA, et al. Final Results of a randomized controlled phase III trial (TAX 325) comparing Docetaxel (T) combined with cisplatin (c) and 5-flourouracil (F) to CF in Patients with metastatic gastric adenocarcinoma (MCG). Proc Am Soc Clin Oncol. 2005;23(16s):4002
  24. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826–1834
  25. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976–1983
  26. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58:959–965
  27. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601
  28. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma (An immunohistochemical study correlated with clinicopathologic findings and DNA amplification). Cancer. 1994;74:795–804
  29. Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res. 2003;9:6461–6468
  30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  31. Suntharalingam M, Dipetrillo T, Ackerman P, et al. Cetuximab, paclitaxel, carboplatin, and radiation for esophageal and gastric cancer. Proc Am Soc Clin Oncol. 2006;24:185s;(abstr 4029)
  32. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19:554–568
  33. Ng T, Dipetrillo T, Purviance J, et al. Multimodality treatment of esophageal cancer: A review of the current status and future directions. Curr Oncol Rep. 2006;8:174–182
  34. Safran H, DiPetrillo T, Nadeem A, et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: A phase I study. Cancer Invest. 2004;22:670–677
  35. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005;23:254–266
  36. Mantraradi RV, Fineberg N, Ansari R, et al. A Phase II study of cisplatin, 5-fluorouracil, radiation and celocoxib in patients with resectable esophageal cancer: Updated results from the Hoosier Oncology Group Study. J Clin Oncol. 2004;22:4042
  37. Suntharalingam M, Moughan J, Coia LR, et al. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol. 2005;23:2325–2331

PII: S1053-4296(06)00090-7

doi: 10.1016/j.semradonc.2006.09.008

Seminars in Radiation Oncology
Volume 17, Issue 1 , Pages 22-28 , January 2007

Article Tools